BioLife Solutions, Inc.

NasdaqCM:BLFS Voorraadrapport

Marktkapitalisatie: US$1.2b

BioLife Solutions Beheer

Beheer criteriumcontroles 2/4

De CEO BioLife Solutions is Rod de Greef, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.39M, bestaande uit 3.1% salaris en 96.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 1.74M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.1 jaar en 16 jaar.

Belangrijke informatie

Rod de Greef

Algemeen directeur

US$6.4m

Totale compensatie

Percentage CEO-salaris3.1%
Dienstverband CEO1.1yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn1.1yrs
Gemiddelde ambtstermijn bestuur16yrs

Recente managementupdates

Recent updates

Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Nov 15
Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Aug 30
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

Aug 14
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05
A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14
Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13
Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11
Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17
Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Aug 11
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

May 06
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Feb 22
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Jan 10
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

BioLife: What The Future Holds

Oct 19

Analyse CEO-vergoeding

Hoe is Rod de Greef's beloning veranderd ten opzichte van BioLife Solutions's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$49m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$6mUS$199k

-US$66m

Sep 30 2023n/an/a

-US$79m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$450k

-US$140m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$96m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$1mUS$412k

-US$9m

Sep 30 2021n/an/a

US$5m

Jun 30 2021n/an/a

US$4m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$391k

US$2m

Sep 30 2020n/an/a

US$7m

Jun 30 2020n/an/a

US$16m

Mar 31 2020n/an/a

US$39m

Dec 31 2019US$1mUS$403k

-US$2m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$39m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$490kUS$350k

-US$25m

Sep 30 2018n/an/a

US$1m

Jun 30 2018n/an/a

-US$146k

Mar 31 2018n/an/a

-US$2m

Dec 31 2017US$520kUS$300k

-US$3m

Compensatie versus markt: De totale vergoeding ($USD 6.39M ) Rod } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.50M ).

Compensatie versus inkomsten: De vergoeding van Rod is gestegen terwijl het bedrijf verliesgevend is.


CEO

Rod de Greef (64 yo)

1.1yrs

Tenure

US$6,387,586

Compensatie

Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Roderick de Greef
CEO & Chairman1.1yrsUS$6.39m0.14%
$ 1.7m
Troy Wichterman
Chief Financial Officer3yrsUS$1.70m0.27%
$ 3.2m
Karen Foster
Chief Quality & Operations Officerless than a yearUS$1.12m0.34%
$ 4.1m
Aby Mathew
Chairman of Scientific Advisory Board4.9yrsUS$1.35m0.61%
$ 7.4m
Sean Werner
Chief Technology Officerno datageen gegevensgeen gegevens
Todd Berard
Chief Commercial Officerno dataUS$734.45k0.23%
$ 2.8m
Sarah Aebersold
Chief Human Resources Officer3.8yrsgeen gegevens0.13%
$ 1.6m

1.1yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BLFS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Roderick de Greef
CEO & Chairman1.8yrsUS$6.39m0.14%
$ 1.7m
Aby Mathew
Chairman of Scientific Advisory Boardno dataUS$1.35m0.61%
$ 7.4m
Shelly Heimfeld
Member of Scientific Advisory Board18.1yrsgeen gegevensgeen gegevens
Scott Burger
Member of Scientific Advisory Board17.2yrsgeen gegevensgeen gegevens
Dayong Gao
Member of Scientific Advisory Board18.1yrsgeen gegevensgeen gegevens
Andrew Hinson
Member of the Scientific Advisory Boardno dataUS$284.00kgeen gegevens
Erik Woods
Member of Scientific Advisory Board17.2yrsgeen gegevensgeen gegevens
Lizabeth Cardwell
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Amy DuRoss
Independent Lead Director3.6yrsUS$269.17k0.039%
$ 472.8k
Joydeep Goswami
Independent Director3.1yrsUS$250.00k0.064%
$ 776.3k
Colleen Delaney
Member of Scientific Advisory Board16yrsgeen gegevensgeen gegevens
John McMannis
Member of Scientific Advisory Board12.8yrsgeen gegevensgeen gegevens

16.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BLFS zijn ervaren en ervaren (gemiddelde ambtstermijn van 16 jaar).